Scott Struthers, Crinetics CEO
FDA rejects Crinetics' current PhII design for hyperinsulinism drug
The FDA has put a stop to Crinetics’ plans for a Phase II trial on its congenital hyperinsulinism drug, the company announced Monday morning. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
